Arcturus Therapeutics' COVID-19 Booster Clinical Trial Show Encouraging Neutralizing Antibody Responses

Arcturus Therapeutics Holdings Inc ARCT has announced updated data Phase 1/2 booster trial of ARCT-154 and ARCT-165, its investigational, self-amplifying mRNA COVID-19 vaccine candidates targeting the variants of concern.

• Data from the Phase 1/2 booster trial show that both ARCT-154 and ARCT-165, when administered as low-dose (5 mcg) boosters at least five months after Pfizer Inc's PFE - BioNTech SE's BNTX Comirnaty immunization, demonstrated robust antibody responses.
• Related: Arcturus Shares Shoot Higher After Additional Data From COVID-19 Vaccine Programs.
• Neutralizing antibody concentrations were maintained between 15 and 29 days post-administration. 
• These results are expected to support further clinical development of these candidates as booster vaccines.
• Price Action: ARCT shares are down 6.47% at $23.00 during the premarket session on Monday's last check.